Nucleoside Analogues Toxicities Related to Mitochondrial Dysfunction: Focus on HIV-Infected Children

De Martino M. , Tovo P.A. , Balducci M. , Galli L. , Gabiano C. , Rexxa G. , & Pezzotti P. for the Italian Register for HIV Infection in Children, and the Italian National AIDS Registry. Reduction in mortality with availability of anti-retroviral therapy for children with perinatal HIV-1 infection. Journal of the American Medical Association 2000; 184: 190–197.

Gerard Y. , Maulin L. , Yazdanpanah Y. , De La Tribonnaire X. , Amiel C. , Maurage C.A. , Robin S. , Sablonniere B. , Dhennain C. , & Mouton Y. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000; 14: 2723–2730.

John M. , Moore C.B. , James I.R. , Nolan D. , Upton R.P. , McKinnon E.J. , & Mallal S.M. Chronic hyperlactataemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717–723.

Boubaker K. , Flepp M. , Sudre P. , Furrer H. , Haensel A. , Hirschel B. , Boggian K. , Chave J.P. , Bernasconi E. , Egger M. , Opravil M. , Rickenbach M. , Franciolo P. , & Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clinical Infectious Diseases 2001; 33: 1931–1937.

Moyle G.J. , Datta D. , Mandalia S. , Morlese J. , Asboe D. , & Gazzard B.G. Hyperlactatemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 14: 1341–1349.

John M. , & Mallal S. Hyperlactactaemia syndromes in people with HIV infection. Current Opinion in Infectious Diseases 2002; 15: 23–29.

Konig H. , Behr E. , Lower J. , & Kurth R. Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma. Antimicrobial Agents & Chemotherapy 1989; 33: 2109–2114.

Chen C. , Vasquez-Padua M. , & Cheng Y. Effect of anti human immunodefiency virus nucleoside analogues on mitochondrial DNA and its implication for delayed toxicity Molecular Pharmacology 1991; 39: 625–628.

Brinkman K. , ter Hofstede J.M. , Burger D.M. , Smeitink J.A.M. , & Koopmans P.P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway AIDS 1998; 12: 1735–1744.

White A.J. Mitochondrial toxicity and HIV therapy. Sexually Transmitted Infections 2001; 77: 158–173.

Mokrzycki M. , Harris C. , May H. , Laut J. , & Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clinical Infectious Diseases 2000; 30: 198–200.

Lonergan J.L. , Behling C. , Pfander H. , Hassanein T.T. , & Mathews W.C. Hyperlactataemia and hepatic abnormalities in ten human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clinical Infectious Diseases 2000; 31: 162–166.

Coghlan M.E. , Sommadossi J.P. , Jhala N.C. , Many W.J. , Saag M.S. , & Johnson V.A. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clinical Infectious Diseases 2001; 33: 1911–1921.

Falco V. , Rodriguez D. , Ribera E. , Martinez E. , Mirò J.M. , Domingo P. , Diazaraque R. , Arribas J.R. , Gonzales-Garcia J.J. , Montero F. , Sanchez L. , & Pahissa A. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clinical Infectious Diseases 2002; 34: 838–846.

Brinkman K. Management of hyperlactataemia: no need for routine lactate measurements. AIDS 2001; 15: 795–797.

Mizock B.A. , & Falk J.L. Lactic acidosis in critical illness. Critical Care Medicine 1992; 20: 80–93.

Miller K.D. , Cameron M. , Wood L.V. , Dalakas M.C. , & Kovacs J.A. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Annals of Internal Medicine 2000; 133: 192–196.

Church J.A. , Mitchell W.G. , Gonzalez-Gomez I. , Christensen J. , Vu T.H. , Dimauro S. , & Boles R.G. Mitochondrial DNA depletion, near-fatal metabolic acidosis and liver failure in an HIV-infected child treated with combination antiretroviral therapy. Journal of Pediatrics 2001; 138: 748–751.

Rey C. , Prieto S. , Medina A. , Perez C. , Concha A. , & Menendez S. Fatal lactic acidosis during antiretroviral therapy. Pediatric Critical Care Medicine 2003; 4: 485–487.

Bissuel F. , Bruneel F. , Habersetzer F. , Chassard D. , Cotte L. , Chevallier M. , Bernuau J. , Lucet J.C. , & Trepo C. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. Journal of Internal Medicine 1994; 235: 367–371.

Bleeker-Rovers C.P. , Kadir S.W. , van Leusen R. , & Richter C. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient. Netherlands Journal of Medicine 2000; 57: 190–193.

Fortgang I.S. , Belitsos P.C. , Chaisson R.E. , & Moore R.D. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analogue antiretroviral therapy American Journal of Gastroenterology 1995; 90: 1433–1436.

Hofstede H.J.M. , de Marie S. , Foudraine N.A. , Danner S.A. , & Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. International Journal of STD & AIDS 2000; 11: 611–616.

Noguera A. , Fortuny C. , Sanchez E. , Arthuch R. , Vilaseca M.A. , Munoz-Almagro C. , Pou J. , & Jimenez R. Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. Pediatric Infectious Disease Journal 2003; 22: 778–782.

Desai N. , Mathur M. , & Weedon J. Lactate levels in children with HIV/AIDS on highly active antiretroviral therapy AIDS 2003; 17: 1565–1567.

Lipshultz S.E. , Chanock S. , Sanders S.P. , Colan S.D. , & McIntosh K. Cardiac manifestations of human immunodeficiency infection in infants and children. American Journal of Cardiology 1989; 63: 1489–1497.

Tovo P.A. , de Martino M. , Gabiano C. , Cappello N. , D'Elia R. , & Loy A. Prognostic factors and survival in children with perinatal HIV-1 infection. Lancet 1992; 339: 1249–1253.

Luginbuhul L.M. , Orav E.J. , McIntosh K. , & Lipshultz S.E. Cardiac morbidity and related mortality in children with HIV infection. Journal of the American Medical Association 1993; 269: 2869–2875.

Turner B.J. , Denison M. , Eppes S.C. , Houchens R. , Fanning T. , & Markson L.E. Survival experience of 789 children with the acquired immunodeficiency syndrome. Pediatric Infectious Disease Journal 1993; 12: 310–320.

Grenier M.A. , Karr S.S. , Rakusan T.A. , & Martin G.R. Cardiac disease in children with HIV: relationship of cardiac disease to HIV symptomatology. Pediatric AIDS & HIV Infection 1994; 5: 174–179.

Italian Register for HIV Infection in Children. Features of children perinatally infected with HIV-1 surviving longer than 5 years. Lancet 1994; 343: 191–195.

Lipshultz S.E. , Orav E.J. , Sanders S.P. , & Colan S.D. Immunoglobulin and left ventricular struture and function in paediatric HIV infection. Circulation 1995; 92: 2220–2225.

Lipshultz S.E. , Bancroft E.A. , & Boller A.M. Cardiovascular manifestations of HIV infection in children. In The Science and Practice of Pediatric Cardiology. 1997 2nd edn. Edited by Bricker J.T. , Garson A. Jr. , Fisher D.J. , & Neish S.R. . Baltimore, MD: Williams-Wilkins.

Kearney D.L. for the P²C² HIV Study Group. Postmortem cardiomegaly correlates with premortem measurements of left ventricular size in malnourished HIV-infected children. 3rd Conference on Retroviruses & Opportunistic Infections. 28 January-1 February 1996, Washington, DC, USA. Abstract 431.

Lindegren M.L. , Caldwell B. , & Oxtoby M. Paediatric HIV infection in the USA. In A Guide to Pratical Management, 1995; pp. 21–51. Edited by Mok J.Y.Q. , & Newell M-L . New York: Cambridge University Press.

Lipshultz S.E. for the P²C² HIV Study Group. Cardiac dysfunction predicts mortality in HIV-infected children: the prospective NHLBI P²C² Study. 3rd Conference on Retroviruses & Opportunistic Infections. 28 January-1 February 1996, Washington DC, USA. Abstract 415.

Lobato M.N. , Caldwell B. , Ng P. , & Oxtoby M.J. Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. Journal of Pediatrics 1995; 126: 710–715.

Lipshultz S.E. , Easley K. , Kaplan S. , Bricker J.T. , Starc T. , Lai W. , Moodie D. , & Colan S.D. for the P²C² Study Group. The relation between progressive immune dysfunction and ventricular dysfunction: the prospective NHLBI P²C² study. 2nd National Conference on Human Retroviruses & Related Infections. 29 January-2 February 1995, Washington DC, USA. Abstract 193.

Lamperth T. , Dalakas M.C. , Dagani F. , Anderson J. , & Ferrari R. Abnormal skeletal and cardiac muscle mitochondrial in vitro and in an animal model. Laboratory Investigations 1991; 6: 742–751.

Gerschenson M. , Erhart S.W. , Paik C.Y. , Nagashima K. , Skopels B. , Harbaugh S.W. , Harbaugh J.W. , Quan W. , & Poirier M.C. Fetal mitochondrial heart and skeletal muscle damage in Erytrocebus patas monkeys exposed in utero 3′-azido-3′-deoxythymidine. AIDS Research & Human Retroviruses 2000; 16: 635–644.

Lewis W. , Grupp I. , Grupp G. , Hoit B. , Morris R. , Samarel A.M. , Bruggeman L. , & Klotman P. Cardiac dysfuction in the HIV-1 transgenic mouse treated with zidovudine. Laboratory Investigations 2000; 80: 187–197.

Rerkpattanapipat P. , Wongpraparut N. , Jacobs L.E. , & Kotler M.N. Cardiac manifestations of acquired immunodeficiency syndrome. Archives of Internal Medicine 2000; 160: 602–608.

Herskowitz A. , Willoughby S.B. , Baughman K.I. , Schulman S.P. , & Bartleit J.D. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Annals of Internal Medicine 1992, 18: 1260–1265.

Cardoso J.S. , Moura B. , Mota-Miranda A. , Goncalves F.R. , & Lecour H. Zidovudine therapy and left ventricular function and mass in human immunodeficiency virus-infected patients. Cardiology 1997; 88: 26–28.

Steinherz L. , Broschstein J.A. , & Robins J. Cardiac involvement in congenital acquired immunodeficiency syndrome. American Journal of Diseases of Children 1986; 140: 1241–1244.

Joshi V.V. , Gadol C. , Connor E. , Oleske J.M. , Mendelson J. , & Marin-Garcia J. Dilated cardiomyopathy in children with acquired immunodeficiency syndrome: a pathologic study of five cases. Human Pathology 1988; 19: 69–73.

Lipshultz S.E. , Orav E.J. , Sanders S.P. , Hale A.R. , McIntosh K. , & Colan S.D. Cardiac structure and function in children with human immunodeficiency infection treated with zidovudine. New England Journal of Medicine 1992; 327: 1260–1265.

Lipshultz S.E. , Kirk A. , Easley M.S. , Orav E.J. , Kaplan S. , Starc T.J. , Bricker T. , Lai W.W. , Moodie D.S. , McIntosh K. , Schluchter M.D. , & Colan S.D. Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 1998; 97: 1246–1256.

Lipshultz S.E. , Kirk A. , Easley M.S. , Orav E.J. , Kaplan S. , Starc T.J. , Bricker T. , Lai W.W. , Moodie D.S. , McIntosh K. , Schluchter M.D. , & Colan S.D. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. New England Journal of Medicine 2000; 343: 759–766.

Domanski M.J. , Sloas M.M. , Follmann D.A. , Scalise P.P. , Tucker E.E. , Egan D. , & Pizzo P.A. Effect of zidovudine and didanosine on heart function in children infected with human immunodeficiency virus. Journal of Pediatrics 1995; 127: 137–146.

Saulsbury F.T. Resolution of organ-specific complications of immunodeficiency virus infection in children with use of highly active antiretroviral therapy. Clinical Infectious Diseases 2001; 32: 464–468.

Cornblath D.R. , & McArthur J.C. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1998; 38: 794–796.

Fuller G.N. , Jacobs J.M. , & Guiloff R.J. Nature and incidence of peripheral nerve syndromes in HIV infection. Journal of Neurology Neurosurgery & Psychiatry 1993; 56: 372–381.

Yarchoan R. , Perno C.F. , Thomas R.V. , Klecker R.W. , Allain J.P. , Wills R.J. , McAtee N. , Fischl M.A. , Dubinsky R. , McNeely M.C. , Mitauya H. , Pluda J.M. , Lawley T.J. , Luther M. , Safai B. , Collins J.M. , Myers C.E. , & Broder S. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine. Lancet 1988; 1: 76–82.

Merigan T.C. , Skowron G. , Bozzette S.A. , Richman D. , Uttamchandani R. , Fischi M. , Schooley R. , Hirsch M. , Soo W. , & Pettinelli C. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Annals of Internal Medicine 1989; 110: 189–194.

Fischi M.A. , Olson R.M. , Follansbee S.E. , Lalezari J.P. , Henry D.H. , Frame P.T. , Remick S.C. , Salgo M.P. , Lin A.H. , & Nauss-Karol C. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Annals of Internal Medicine 1993; 118: 762–769.

Package Insert Videx (didanosine). October 1991. New York: Bristol-Meyer-Squibb.

Rozeneweig M. , McLaren C. , Beltangady M. , Ritter J. , Canetta R. , Schacter L. , Kelley S. , Nicaise C. , Smaldone L. , & Dunkle L. Overview of phase I trials of 2′,3′-dideoxyinosine (ddI) conducted on adult patients. Reviews of Infectious Diseases 1990; 12: 570–575.

Keilbaugh S.A. , Prusoff W.H. , & Simpson V.W.V. The PC12 cell as a model for studies of mechanism of induction of peripheral neuropathy by anti-HIV dideoxynucleoside analogs. Biochemical Pharmacology 1991; 42: R5–R8.

Dalakas M.C. , Semino-Mora C. , & Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3′-dideoxycitidine (ddC). Laboratory Investigations 2001; 81: 1537–1544.

Simpson D.M. , & Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1995; 9: 153–161.

Famularo G. , Moretti S. , Marcellini S. , Trinchieri V. , Tzantzoglou S. , Santini G. , Longo A. , & De Simone C. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral NRTI. AIDS 1997; 11: 185–190.

Forloni G. , Angeretti N. , & Smiroldo S. Neuroprotective activity of acetyl-l-carnitine: studies in vitro. Journal of Neuroscience Research 1994; 37: 92–96.

Civitello L.A. Neurologic complications of HIV infection in children. Pediatric Neurosurgery 1991; 17: 104–112.

Pizzo P.A. , Butler K. , Balis F. , Brouwers E. , Hawkins M. , Eddy J. , Einloth M. , Falloon J. , Husson R. , & Jarosinski P. Dideoxycitidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. Journal of Pediatrics 1990; 117: 799–808.

Raphael S.A. , Price M.L. , Lischner H.W. , Griffin J.W. , Grover W.D. , & Bagarsa O. Inflammatory demyelinating polyneuropathy in a child with symptomatic human immunodeficiency virus infection. Journal of Pediatrics 1991; 118: 242–245.

Floeter M.K. , Civitell L.A. , Everett C.R. , Dambrosia J. , & Luciano C.A. Peripheral neuropathy in children with HIV infection. Neurology 1997; 49: 207–212.

Prufer de Q.C. , Araujo A. , Nascimento O.J.M. , & Garcia O.S. Distal sensory polyneuropathy in a cohort of HIV-infected children over five years of age. Pediatrics 2000; 106: E35.

Komiya Y. Axonal regeneration in bifurcating axons of dorsal root ganglion cells. Experimental Neurology 1981; 73: 824–826.

Gamstorp I. Normal nerve conduction velocity of ulnar median and peroneal nerves in infancy, childhood and adolescence. Acta Paediatrica 1963; 14 (Suppl 146): 68–76.

Schambelan M. , Benson C.A. , Carr A. , Currier J.S. , Dube M.P. , Gerber J.G. , Grinspoon S.K. , Grunfeld C. , Kotler D.P. , Mulligan K. , Powderly W.G. , & Saag M.S. Management of metabolic complication associated with antiretroviral therapy for HIV-1 infection: recommendation of an International AIDS Society-USA panel. Journal of Acquired Immune Deficiency Syndromes 2002; 31: 257–275.

Bernasconi E. , Boubaker K. , Junghans C. , Flepp M. , Furrer H.J. , Haensel A. , Hirschel B. , Boggian K. , Chave J.P. , Opravil M. , Weber R. , Rickenbach M. , & Telenti A. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes 2002; 31: 50–55.

Health K.V. , Hogg R.S. , Singer J. , Chan K.J. , O'Shaughnessy M.V. , & Montaner J.S. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. Journal of Acquired Immune Deficiency Syndromes 2002; 30: 440–447.

Brambilla P. , Bricalli D. , Sala N. , Renzetti F. , Manzoni P. , Vanzulli A. , Chiumello G. , di Natale B. , & Viganò A. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 2001; 15: 2415–2422.

Arpadi S.M. , Cuff P.A. , Horlick M. , Wang J. , & Kotler D.P. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. Journal of Acquired Immune Deficiency Syndromes 2001; 27: 30–34.

Seidell J.C. , Bakker C.J.G. , & Van der Kooy K. Imaging techniques for measuring adipose tissue distribution. A comparison between computed tomography and 1.5 T magnetic resonance. American Journal of Clinical Nutrition 1990; 51: 953–957.

Ellis K.J. , Shypailo R.J. , Pratt J.A. , & Pond W.G. Accuracy of dual-energy X-ray absorptiometry for body-composition measurements in children. American Journal of Clinical Nutrition 1994; 60: 660–665.

He Q. , Horlick M. , Fedun B. , Wang J. , Pierson R.N. , Heshka S. , & Gallagher D. Trunk fat and blood pressure in children through puberty. Circulation 2002; 105: 1093–1096.

Lohman T.G. , Roche F. , & Martorell R. (Editors). Anthropometric standardization reference manual, 1988. Champaign, IL, USA: Human Kinetics Books.

Jaquet D. , Levine M. , Ortega-Rodriguez E. , Faye A. , Polak M. , Vilmer E. , & Levy-Marchal C. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000; 14: 2123–2128.

Amaya R.A. , Kozinetz C.A. , McMeans A. , Schwarzwald H. , & Kline M.W. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal 2002; 21: 405–410.

Viganò A. , Mora S. , Testolin C. , Beccio S. , Schneider L. , Bricalli D. , Vanzulli A. , Manzoni P. , & Brambilla P. Increased lipodystrophy with increased exposure to highly active antiretroviral therapy in HIV-infected children. Journal of Acquired Immune Deficiency Syndromes 2003; 32: 482–489.

European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004; 18: 1443–1451.

Lichtenstein K.A. , Delaney K.M. , Armon C. , Ward D.J. , Moorman A.C. , Wood K.C. , & Holmberg S.D. Incidence of and risk factor for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes 2003; 32: 48–56.

Carr A. , Samaras K. , Burton S. , Law M. , Freund J. , Chisholm D.J. , & Cooper D.A. A syndrome of peripheral lipodystrophy hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51–F58.

Mallal S.A. , John M. , Moore C.B. , James I.R. , & McKinnon E.J. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309–1316.

Cossarizza A. , Mussini C. , & Viganò A. Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders? BioEssays 2001; 23: 1070–1080.

Moyle G. Mitochondrial toxicity hypothesis for lipoatrophy: a refutation. AIDS 2001; 15: 413–414.

Walker U.A. , Bickel M. , Lutke Volksbeck S.I. , Ketelsen U.P. , Schofer H. , Setzer B. , Venhoff N. , Rickerts V. , & Staszewski S. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2002; 29: 117–121.

Shikuma C.M. , Hu N. , Milne C. , Yost F. , Waslien C. , & Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15: 1801–1809.

Hammond E. , Nolan D. , James I. , Metcalf C. , & Mallal S. Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy. AIDS 2004; 18: 815–827.

Martin A. , Smith D.E. , Carr A. , Ringland C. , Amin J. , Emery S. , Hoy J. , Workman C. , Doong N. , Freund J. , & Cooper D.A. ; Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18: 1029–1036.

McComsey G.A. , Ward D.J. , Hessenthaler S.M. , Sension M.G. , Shalit P. , Lonergan J.T. , Fisher R.L. , Williams V.C. , & Hernandez J.E. ; Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV 1-Positive Subjects (TARHEEL; ESS40010) Study Team. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clinical Infectious Diseases 2004; 38: 263–270.

McComsey G.A. , Paulsen D.M. , Lonergan J.T. , Hessenthaler S.M. , Hoppel C.L. , Williams V.C. , Fisher R.L. , Cherry C.L. , White-Owen C. , Thompson K.A. , Ross S.T. , Hernandez J.E. , & Ross L.L. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19: 15–23.

Cossarizza A. , Riva A. , Pinti M. , Ammannato S. , Fedeli P. , Mussini C. , Esposito R. , & Galli M. Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antiviral Therapy 2003; 8: 315–321.

Cossarizza A. , Pinti M. , Moretti L. , Bricalli D. , Bianchi R. , Troiano L. , Fernandez M.G. , Balli F. , Brambilla P. , Mussini C. , & Viganò A. Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy. Journal of Infectious Diseases 2002; 185: 299–305.

Ogedegbe A.E. , Thomas D.L. , & Diehi A.M. Hyperlactatemia syndromes associated with HIV therapy. Lancet Infectious Diseases 2003; 3: 329–337.

Chinnery P.F. , & Bindoff L.A. ; European neuromuscular center. 116th ENMC international workshop: the treatment of mitochondrial disorders, 14th-16th March 2003, Naarden, The Netherlands. Neuromuscular Disorders 2003; 13: 757–764.